Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry.

lymph nodes overall survival perihilar cholangiocarcinoma recurrence-free survival resection margin

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
12 May 2022
Historique:
received: 25 03 2022
revised: 09 05 2022
accepted: 10 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

Background: Lymph node metastasis and positive resection margins have been reported to be major determinants of overall survival (OS) and poor recurrence-free survival (RFS) for patients who underwent resection for perihilar cholangiocarcinoma (pCCA). However, the prognostic value of positive lymph nodes independently from resection margin status on OS has not been evaluated. Methods: From the European Cholangiocarcinoma (ENSCCA) registry, patients who underwent resection for pCCA between 1994 and 2021 were included in this retrospective cohort study. The primary outcome was OS stratified for resection margin and lymph node status. The secondary outcome was recurrence-free survival. Results: A total of 325 patients from 11 different centers and six European countries were included. Of these, 194 (59.7%) patients had negative resection margins. In 113 (34.8%) patients, positive lymph nodes were found. Lymph node status, histological grade, and ECOG performance status were independent prognostic factors for survival. The median OS for N0R0, N0R1, N+R0, and N+R1 was 38, 30, 18, and 12 months, respectively (p < 0.001). Conclusion: These data indicate that in the presence of positive regional lymph nodes, resection margin status does not determine OS or RFS in patients with pCCA. Achieving negative margins in patients with positive nodes should not come at the expense of more extensive surgery and associated higher mortality.

Identifiants

pubmed: 35625993
pii: cancers14102389
doi: 10.3390/cancers14102389
pmc: PMC9140174
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : the European Association for the Study of the Liver (EASL; Registry grant awards 2016 and 2019 to JMB)
ID : grant awards 2016 and 2019
Organisme : Incyte Bioscience International Sàrl
ID : grant award 2020
Organisme : European Union's Horizon 2020 Research and Innovation Program
ID : 825510

Références

J Hepatol. 2019 Jul;71(1):115-129
pubmed: 30797051
J Gastrointest Surg. 2020 Jul;24(7):1612-1618
pubmed: 30756314
Ann Surg. 2003 Jul;238(1):84-92
pubmed: 12832969
Arch Surg. 2012 Jan;147(1):26-34
pubmed: 22250108
Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14
pubmed: 22504095
Langenbecks Arch Surg. 2021 Aug;406(5):1499-1509
pubmed: 34075473
Cancers (Basel). 2021 Jul 21;13(15):
pubmed: 34359560
Surg Endosc. 2016 Oct;30(10):4163-73
pubmed: 26895909
Ann Oncol. 2015 Sep;26(9):1930-1935
pubmed: 26133967
Ann Surg Oncol. 2016 Dec;23(Suppl 5):904-910
pubmed: 27586005
Virchows Arch. 2019 Oct;475(4):435-443
pubmed: 31446465
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Ann Surg. 2013 Jul;258(1):129-40
pubmed: 23059502
Ann Surg Oncol. 2018 Apr;25(4):845-847
pubmed: 28752469
HPB (Oxford). 2017 Aug;19(8):735-740
pubmed: 28549744
J Gastrointest Surg. 2020 Jul;24(7):1619-1629
pubmed: 31147975
JAMA Surg. 2020 Apr 1;155(4):300-311
pubmed: 32101269
Br J Surg. 2018 Oct;105(11):1408-1416
pubmed: 29999515
Liver Int. 2019 May;39 Suppl 1:143-155
pubmed: 30843343
Ann Surg Oncol. 2020 Oct;27(11):4171-4180
pubmed: 32363510
Int J Clin Oncol. 2021 Sep;26(9):1575-1586
pubmed: 34160742
ANZ J Surg. 2020 Sep;90(9):1604-1614
pubmed: 31840387
J Hepatobiliary Pancreat Surg. 2000;7(2):128-34
pubmed: 10982604
J Gastrointest Oncol. 2021 Apr;12(2):806-818
pubmed: 34012668
Cancer Res Treat. 2020 Jul;52(3):886-895
pubmed: 32164049
J Hepatol. 2022 May;76(5):1109-1121
pubmed: 35167909
J Am Coll Surg. 2015 Dec;221(6):1041-9
pubmed: 26454735
World J Gastroenterol. 2020 Jun 28;26(24):3318-3325
pubmed: 32655260
Ann Surg Oncol. 2021 Nov;28(12):7719-7729
pubmed: 33956275

Auteurs

Lynn E Nooijen (LE)

Department of Surgery, Amsterdam UMC-Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Cancer Center Amsterdam, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands.

Jesus M Banales (JM)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastián, Spain.
National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, "Instituto de Salud Carlos III" (ISCIII), 28029 Madrid, Spain.
Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31080 Pamplona, Spain.
Ikerbasque, Basque Foundation for Science, 48009 Bilbao, Spain.

Marieke T de Boer (MT)

Section of HPB Surgery & Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.

Chiara Braconi (C)

The Royal Marsden NHS Trust, London SW3 6JJ, UK.

Trine Folseraas (T)

Norwegian PSC Research Center and Section of Gastroenterology, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University Hospital Rikshospitalet, 0372 Oslo, Norway.

Alejandro Forner (A)

BCLC Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBEREHD, University Barcelona, 08036 Barcelona, Spain.

Waclaw Holowko (W)

Department of General, Transplant and Liver Surgery, Medical University of Warsaw, 02-091 Warsaw, Poland.

Frederik J H Hoogwater (FJH)

Section of HPB Surgery & Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.

Heinz-Josef Klümpen (HJ)

Cancer Center Amsterdam, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands.
Department of Medical Oncology, Amsterdam UMC-Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Bas Groot Koerkamp (B)

Department of Surgery, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Angela Lamarca (A)

Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.

Adelaida La Casta (A)

Department of Medical Oncology, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastián, Spain.

Flora López-López (F)

Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.

Laura Izquierdo-Sánchez (L)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastián, Spain.

Alexander Scheiter (A)

Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany.

Kirsten Utpatel (K)

Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany.

Rutger-Jan Swijnenburg (RJ)

Cancer Center Amsterdam, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands.
Department of Surgery, Amsterdam UMC-Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Geert Kazemier (G)

Department of Surgery, Amsterdam UMC-Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Cancer Center Amsterdam, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands.

Joris I Erdmann (JI)

Cancer Center Amsterdam, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands.
Department of Surgery, Amsterdam UMC-Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Classifications MeSH